Talazoparib
VIDEO: Immunotherapy may offer next big breakthrough in advanced prostate cancer
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
VIDEO: New targets sought for advanced prostate cancer treatment
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
VIDEO: PSMA PET imaging 'single most important advance' in advanced prostate cancer
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
VIDEO: Androgen receptor pathway inhibitors ‘have transformed’ prostate cancer management
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
VIDEO: Upfront use of PARP, ARPI combination may offer greater survival benefit
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
Combination extends survival in metastatic prostate cancer
The addition of talazoparib to enzalutamide extended OS among men with metastatic castration-resistant prostate cancer, according to the agent’s manufacturer.
Providers support approvals of therapies for prostate cancer, lymphoma, heart disease
An analysis of online conversations among health care professionals on social media in June revealed overwhelming support for FDA approvals of therapies for prostate cancer and lymphoma.
VIDEO: ASCO highlights in lung cancer outside of NSCLC
Healio spoke with Karen L. Reckamp, MD, professor in medicine and director of the division of medical oncology at Cedars-Sinai Medical Center, about key studies in lung cancer from ASCO Annual Meeting.
FDA approves Talzenna regimen for certain men with metastatic prostate cancer
FDA approved talazoparib plus enzalutamide for treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
Talazoparib regimen improves outcomes among subset of men with metastatic prostate cancer
CHICAGO — Adding talazoparib to enzalutamide reduced the risk for disease progression or death by 55% in certain men with metastatic castration-resistant prostate cancer, results of the randomized phase 3 TALAPRO-2 trial showed.